Coinfection (HIV/CMV)

Two Therapies Equally Effective for CMV Esophagitis

Published in AIDS Weekly, March 30th, 1998

Foscarnet and ganciclovir appear to be similarly effective and safe in the induction therapy of AIDS-related cytomegalovirus esophagitis, according to a report from the Italian Cytomegalovirus Study Group.

"Considering that the toxicity profile of the two compounds is completely different, the choice of anti-cytomegalovirus (CMV) agent should be tailored to the individual patient according to the presence of either relative or absolute contraindication to one of the two drugs, as well as viral resistance, toxicity, concomitant therapies, and patient preference," F. Parente and colleagues wrote ("Treatment of Cytomegalovirus Esophagitis in Patients with Acquired Immune...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-03-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry